Enlivex Therapeutics Valuation
| ENLV Stock | ILA 428.50 28.30 7.07% |
At this time, the firm appears to be overvalued. Enlivex Therapeutics shows a prevailing Real Value of 375.31 per share. The current price of the firm is 428.5. Our model computes the value of Enlivex Therapeutics from reviewing the firm fundamentals such as Shares Owned By Insiders of 12.19 %, price to book of 1.23 X, and Current Valuation of 147.66 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Enlivex Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Enlivex Therapeutics is based on 3 months time horizon. Increasing Enlivex Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Enlivex Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enlivex Stock. However, Enlivex Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 428.5 | Real 375.31 | Hype 400.2 | Naive 441.51 |
The real value of Enlivex Stock, also known as its intrinsic value, is the underlying worth of Enlivex Therapeutics Company, which is reflected in its stock price. It is based on Enlivex Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Enlivex Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Enlivex Therapeutics helps investors to forecast how Enlivex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enlivex Therapeutics more accurately as focusing exclusively on Enlivex Therapeutics' fundamentals will not take into account other important factors: Enlivex Therapeutics Total Value Analysis
Enlivex Therapeutics is currently forecasted to have takeover price of 147.66 M with market capitalization of 273.23 M, debt of 615 K, and cash on hands of 90.6 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Enlivex Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
147.66 M | 273.23 M | 615 K | 90.6 M |
Enlivex Therapeutics Asset Utilization
One of the ways to look at asset utilization of Enlivex is to check how much profit was generated for every dollar of assets it reports. Enlivex Therapeutics shows a negative utilization of assets of -0.19 percent, losing 0.001888 for each of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each of assets it shows. Put another way, asset utilization of Enlivex Therapeutics shows how discouraging it operates for each spent on its assets.Enlivex Therapeutics Ownership Allocation
Enlivex Therapeutics holds a total of 18.41 Million outstanding shares. Enlivex Therapeutics shows 12.19 percent of its outstanding shares held by insiders and 9.53 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Enlivex Therapeutics Profitability Analysis
Net Loss for the year was (14.47 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Enlivex Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Enlivex Therapeutics and how it compares across the competition.
About Enlivex Therapeutics Valuation
The stock valuation mechanism determines Enlivex Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Enlivex Therapeutics. We calculate exposure to Enlivex Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Enlivex Therapeutics's related companies.Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. ENLIVEX THERAPEUTI operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 50 people.
8 Steps to conduct Enlivex Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Enlivex Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Enlivex Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Enlivex Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Enlivex Therapeutics' revenue streams: Identify Enlivex Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Enlivex Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Enlivex Therapeutics' growth potential: Evaluate Enlivex Therapeutics' management, business model, and growth potential.
- Determine Enlivex Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Enlivex Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |